Nasdaq · Healthcare
Roivant Sciences Ltd. (ROIV)
As-reported financials and recent SEC filings for Roivant Sciences Ltd., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$8.3M
Net income
$-299.8M
Net margin
—
Diluted EPS
$-0.54
ROE
-5.7%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M |
| Gross profit | — | — | — | — | — |
| Operating income | $-515.1M | $-1.00B | $4.50B | $-906.8M | $-1.35B |
| Net income | $-299.8M | $-172.0M | $4.35B | $-1.01B | $-845.3M |
| Diluted EPS | $-0.54 | $-0.24 | $5.23 | $-1.42 | $-1.26 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-01
View on EDGAR →1442026-06-30
View on EDGAR →1442026-06-30
View on EDGAR →42026-06-30
View on EDGAR →Largest Healthcare peers
Go deeper on ROIV
Search Roivant Sciences Ltd.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.